Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinucon is an over-the-counter (OTC) multi-symptom combination medication marketed by Ascendis Health (and subsequently Shanur Healthcare) primarily in South Africa. It is formulated to provide relief from sinus congestion, nasal congestion, headaches, and allergy symptoms associated with the common cold, influenza, and allergic rhinitis. The drug contains a combination of four active small molecule ingredients: the antihistamines chlorpheniramine maleate and phenyltoloxamine citrate, and the decongestants phenylephrine hydrochloride and phenylpropanolamine hydrochloride. These components work by blocking histamine H1 receptors to reduce allergic responses like sneezing and itchy eyes, and by stimulating adrenergic receptors to cause vasoconstriction in the nasal mucosa, thereby reducing swelling and congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sinucon.